SurModics (SRDX) Tops Q1 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
SurModics Reports First Quarter Fiscal 2016 Results
January 28, 2016 7:35 AM ESTGAAP Revenue of $16.5 Million, up 16% GAAP EPS of $0.19, Non-GAAP EPS of $0.38 Fiscal 2016 Guidance Reaffirmed
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2016 first quarter, ended December 31, 2015.
The SurModics team had an exceptional first quarter of fiscal 2016, said Gary Maharaj, president and chief executive officer. We delivered outstanding results from our core Medical Device and In Vitro Diagnostic... More
